School of Medicine
Showing 11-20 of 37 Results
Clinical Assistant Professor, Psychiatry and Behavioral Sciences
Current Research and Scholarly InterestsMy research focuses on improving cancer survivorship through better understanding of long-term health outcomes and through the development of theoretically driven, evidence-based behavioral interventions to improve adjustment, risk management, and quality of life. To this end, I lead studies aimed to guide and support patient decision-making and self-management after cancer. Much of my work focuses on the experiences of young adults affected by cancer.
Jonathan S. Berek, MD, MMSc
Laurie Kraus Lacob Professor
BioLaurie Kraus Lacob Professor
Stanford University School of Medicine
Director, Stanford Women’s Cancer Center
Senior Advisor, Stanford Cancer Institute
Executive Director, Stanford Health Communication Initiative
Director, MedArts Films
Stanford Center for Health Education
Shirley R. and Leonard W. Ely, Jr. Professor of the School of Humanities and Sciences
Current Research and Scholarly InterestsWe use genetic, genomic and cell biological approaches to study cell fate acquisition, focusing on cases where cell fate is correlated with asymmetric cell division.
Alfred Woodley Salter and Mabel G. Salter Endowed Professor of Pediatrics
Current Research and Scholarly Interests1. Using iPSC-derived cardiomyocytes to understand hypertrophic cardiomyopathy and heart failure associated with congenital heart disease.
2. Role of alterations in mitochondrial dycamics and function in normal physiology and disease.
3. Differences between R and L ventricular responses to stress,
4. Immune biomarkers of risk after pediatric VAD implantation.
5. Biomarkers for post-transplant lymphoproliferative disorder.
Alice Bertaina MD, PhD
Associate Professor of Pediatrics (Stem Cell Transplantation)
Current Research and Scholarly InterestsDr. Bertaina is a highly experienced clinician and will play a key role in supporting Section Chief Dr. Rajni Agarwal and Clinical Staff in the Stem Cell Transplant Unit at Lucile Packard Children’s Hospital. She will also continue her research on immune recovery and miRNA, understanding the mechanisms underlying immune reconstitution, Graft-versus-Host Disease (GvHD), and leukemia relapse after allogeneic HSCT in pediatric patients affected by hematological malignant and non-malignant disorders.
Baker Family Director of Stanford ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology and of Radiology
BioProfessor Carolyn Bertozzi's research interests span the disciplines of chemistry and biology with an emphasis on studies of cell surface sugars important to human health and disease. Her research group profiles changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection, and uses this information to develop new diagnostic and therapeutic approaches, most recently in the area of immuno-oncology.
Dr. Bertozzi completed her undergraduate degree in Chemistry at Harvard University and her Ph.D. at UC Berkeley, focusing on the chemical synthesis of oligosaccharide analogs. During postdoctoral work at UC San Francisco, she studied the activity of endothelial oligosaccharides in promoting cell adhesion at sites of inflammation. She joined the UC Berkeley faculty in 1996. A Howard Hughes Medical Institute Investigator since 2000, she came to Stanford University in June 2015, among the first faculty to join the interdisciplinary institute ChEM-H (Chemistry, Engineering & Medicine for Human Health). She is now the Baker Family Director of Stanford ChEM-H.
Named a MacArthur Fellow in 1999, Dr. Bertozzi has received many awards for her dedication to chemistry, and to training a new generation of scientists fluent in both chemistry and biology. She has been elected to the Institute of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences; and received the Lemelson-MIT Prize, the Heinrich Wieland Prize, the ACS Award in Pure Chemistry, and the Chemistry of the Future Solvay Prize, among others.
The Bertozzi Group develops chemical tools to study the glycobiology underlying diseases such as cancer, inflammation, tuberculosis and most recently COVID-19. She is the inventor of "bioorthogonal chemistry", a class of chemical reactions compatible with living systems that enable molecular imaging and drug targeting. Her group also developed new therapeutic modalities for targeted degradation of extracellular biomolecules, such as antibody-enzyme conjugates and Lysosome Targeting Chimeras (LYTACs). As well, her group studies NGly1 deficiency, a rare genetic disease characterized by loss of the human N-glycanase.
Several of the technologies developed in the Bertozzi lab have been adapted for commercial use. Actively engaged with several biotechnology start-ups, Dr. Bertozzi cofounded Redwood Bioscience, Enable Biosciences, Palleon Pharmaceuticals, InterVenn Bio, OliLux Bio, Grace Science LLC and Lycia Therapeutics. She is also a member of the Board of Directors of Lilly.
Associate Professor of Medicine (Hematology) and of Genetics
Current Research and Scholarly InterestsThe Bhatt lab is exploring how the microbiota is intertwined with states of health and disease. We apply the most modern genetic tools in an effort to deconvolute the mechanism of human diseases.
Associate Professor of Radiology (Pediatric Radiology) and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsStudies on apoptotic cell death in vivo using the H MRS phenomenon.
Helen M. Blau
Donald E. and Delia B. Baxter Foundation Professor, Director, Baxter Laboratory for Stem Cell Biology and Professor, by courtesy, of Psychiatry and Behavioral SciencesOn Partial Leave from 01/01/2021 To 12/31/2021
Current Research and Scholarly InterestsProf. Helen Blau's research area is regenerative medicine with a focus on stem cells. Her research on nuclear reprogramming and demonstrating the plasticity of cell fate using cell fusion is well known and her laboratory has also pioneered the design of biomaterials to mimic the in vivo microenvironment and direct stem cell fate. Current findings are leading to more efficient iPS generation, cell based therapies by dedifferentiation a la newts, and discovery of novel molecules and therapies.
Douglas W. Blayney
Professor of Medicine (Oncology)
Current Research and Scholarly InterestsImproving the quality of cancer care at Stanford, in our network of care, and nationally